EXPERT CONSENSUS ON THE ROLE OF HEPATITIS-SPECIFIC MAGNETIC CONTRAST IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA
Main Article Content
Abstract
Some consensuses of Korean and Vietnamese experts on the value of hepatobiliary magnetic resonance with liver tissue-specific magnetic contrast agents in diagnosing and screening hepatocellular carcinoma as well as providing results discussion and recommendations on this issue.
Keywords
Hepatocellular carcinoma, magnetic resonance. Liver tissue-specific magnetic contrast agent
Article Details
References
1. Murakami T, Sofue K, Hori M. Diagnosis of Hepatocellular Carcinoma Using Gd-EOB-DTPA MR Imaging. Magn Reson Med Sci. 2021;21(1):168-181. doi:10.2463/mrms.rev.2021-0031
2. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272(3):635-654. doi:10.1148/radiol.14132361
3. Kudo M, Kawamura Y, Hasegawa K, et al. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021;10(3):181-223. doi:10.1159/000514174
4. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(4):583-705. doi:10.3350/cmh.2022.0294
5. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317-370. doi:10.1007/s12072-017-9799-9
6. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. doi:10.1016/j.jhep.2018.03.019
7. Bộ Y Tế. Hướng dẫn chẩn đoán và điều trị ung thư biểu mô tế bào gan. Published online 2020.
8. Park HJ, Lee TY, Kim SY, et al. Hypervascular transformation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement on gadoxetic acid-enhanced MRI: long-term follow-up in a surveillance cohort. Eur Radiol. 2022;32(8):5064-5074. doi:10.1007/s00330-022-08623-8
9. Hanna RF, Miloushev VZ, Tang A, et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol N Y. 2016;41(1):71-90. doi:10.1007/s00261-015-0592-8
10. Kim HD, Lim YS, Han S, et al. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology. 2015;148(7):1371- 1382. doi:10.1053/j.gastro.2015.02.051
11. Jiang H, Wei J, Fu F, et al. Predicting microvascular invasion in hepatocellular carcinoma: A dual-institution study on gadoxetate disodium-enhanced MRI. Liver Int. 2022;42(5):1158-1172. doi:10.1111/liv.15231
12. Ueno A, Masugi Y, Yamazaki K, et al. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol. 2014;61(5):1080-1087. doi:10.1016/j.jhep.2014.06.008
13. Kitao A, Matsui O, Yoneda N, et al. Hepatocellular Carcinoma with β-Catenin Mutation: Imaging and Pathologic Characteristics. Radiology. 2015;275(3):708-717. doi:10.1148/radiol.14141315
14. Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer. 2020;9(5):479-490. doi:10.1159/000509554
2. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272(3):635-654. doi:10.1148/radiol.14132361
3. Kudo M, Kawamura Y, Hasegawa K, et al. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021;10(3):181-223. doi:10.1159/000514174
4. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(4):583-705. doi:10.3350/cmh.2022.0294
5. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317-370. doi:10.1007/s12072-017-9799-9
6. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. doi:10.1016/j.jhep.2018.03.019
7. Bộ Y Tế. Hướng dẫn chẩn đoán và điều trị ung thư biểu mô tế bào gan. Published online 2020.
8. Park HJ, Lee TY, Kim SY, et al. Hypervascular transformation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement on gadoxetic acid-enhanced MRI: long-term follow-up in a surveillance cohort. Eur Radiol. 2022;32(8):5064-5074. doi:10.1007/s00330-022-08623-8
9. Hanna RF, Miloushev VZ, Tang A, et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol N Y. 2016;41(1):71-90. doi:10.1007/s00261-015-0592-8
10. Kim HD, Lim YS, Han S, et al. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology. 2015;148(7):1371- 1382. doi:10.1053/j.gastro.2015.02.051
11. Jiang H, Wei J, Fu F, et al. Predicting microvascular invasion in hepatocellular carcinoma: A dual-institution study on gadoxetate disodium-enhanced MRI. Liver Int. 2022;42(5):1158-1172. doi:10.1111/liv.15231
12. Ueno A, Masugi Y, Yamazaki K, et al. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol. 2014;61(5):1080-1087. doi:10.1016/j.jhep.2014.06.008
13. Kitao A, Matsui O, Yoneda N, et al. Hepatocellular Carcinoma with β-Catenin Mutation: Imaging and Pathologic Characteristics. Radiology. 2015;275(3):708-717. doi:10.1148/radiol.14141315
14. Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer. 2020;9(5):479-490. doi:10.1159/000509554